Asterias Biotherapeutics Inceries A (NYSEAMERICAN:AST) Could Burn Your Long Portfolio After More Shorts

November 10, 2018 - By Ash

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Logo

The stock of Asterias Biotherapeutics Inceries A (NYSEAMERICAN:AST) registered an increase of 6.71% in short interest. AST’s total short interest was 3.59M shares in November as published by FINRA. Its up 6.71% from 3.37M shares, reported previously. With 117,800 shares average volume, it will take short sellers 31 days to cover their AST’s short positions. The short interest to Asterias Biotherapeutics Inceries A’s float is 12.93%.

The stock decreased 1.52% or $0.02 during the last trading session, reaching $1.3. About 352,322 shares traded or 100.77% up from the average. Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) has declined 56.92% since November 10, 2017 and is downtrending. It has underperformed by 72.54% the S&P500.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company has market cap of $72.16 million. The firm develops therapeutic products in the areas of neurology and oncology. It currently has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>